SCHEMBL25623939

SCHEMBL25623939

CC(C)(C)CC1(F)CCN(S(C)(=O)=O)CC1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 10/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM1A O60341 1/20 0.41
NEK2 P51955 2/20 0.37
CYP3A4 P08684 5/20 0.36
CYP2C9 P11712 5/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP1A2 P05177 3/20 0.35
ALDH1A1 P00352 2/20 0.35
HIF1A Q16665 2/20 0.35
USP2 O75604 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP2C19 P33261 5/20 0.35
TSHR P16473 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613288 0.79 CYP2D6 (0.42) CYP2D6SMN1; SMN2NEK2CYP3A4CYP2C9
SCHEMBL25626551 0.78 CYP2D6 (0.41) CYP2D6SMN1; SMN2NEK2CYP3A4CYP2C9
SCHEMBL17507855 0.77 CYP2D6 (0.43) CYP2D6SMN1; SMN2KDM1ANEK2CYP3A4
SCHEMBL15925087 0.76 KDM1A (0.35) KDM1A
Hydrochloric Acid SCHEMBL17507856 0.76 CYP2D6 (0.42) CYP2D6SMN1; SMN2KDM1ANEK2CYP3A4
SCHEMBL25626550 0.74 CYP2D6 (0.53) CYP2D6SMN1; SMN2KDM1ANEK2CYP3A4
SCHEMBL17780236 0.74 KDM1A (0.50) CYP2D6SMN1; SMN2KDM1ANEK2CYP3A4
SCHEMBL15218458 0.73 CYP2D6 (0.50) CYP2D6SMN1; SMN2KDM1ANEK2CYP3A4
SCHEMBL29317676 0.72 GRIN2D (0.37)
SCHEMBL1911575 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 CYP2D6 3553/4885SMN1; SMN2 2369/4885KDM1A 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.